Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04962139 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
A Phase 3 study, sponsored by Oneness Biotech Co..
- Terminated
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT04962139 is a Phase 3 study that was terminated before completion, run by Oneness Biotech Co.. The registered enrollment target is 12 participants.
The verdict
NCT04962139, a Phase 3 study, was terminated before completion, sponsored by Oneness Biotech Co..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary efficacy endpoint for this study is the proportion of subjects with complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by the blinded independent evaluator.
Interventions
- OTHER Vehicle Cream
- DRUG ON101 Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-07-27 |
| Est. Completion | 2022-11-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04962139
The ClinicalTrials.gov registry entry for NCT04962139 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oneness Biotech Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Cream is the first listed.
NCT04962139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04962139 about?
NCT04962139 is a clinical study titled "Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers". The primary efficacy endpoint for this study is the proportion of subjects with complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by the blinded independent evaluator.
What is the current status of trial NCT04962139?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2021-07-27. Estimated completion is 2022-11-29.
What interventions are being tested in trial NCT04962139?
The interventions under investigation include: Vehicle Cream (OTHER), ON101 Cream (DRUG).
Who is sponsoring clinical trial NCT04962139?
This trial is sponsored by Oneness Biotech Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.